Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer

  • Technology appraisal guidance
  • TA851
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Draft scope documents

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators